Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy.

Debiec H, Martin L, Jouanneau C, Dautin G, Mesnard L, Rondeau E, Mousson C, Ronco P.

Am J Transplant. 2011 Oct;11(10):2144-52. doi: 10.1111/j.1600-6143.2011.03643.x. Epub 2011 Aug 9.

2.

Very early recurrence of anti-Phospholipase A2 receptor-positive membranous nephropathy after transplantation.

Blosser CD, Ayalon R, Nair R, Thomas C, Beck LH Jr.

Am J Transplant. 2012 Jun;12(6):1637-42. doi: 10.1111/j.1600-6143.2011.03957.x. Epub 2012 Mar 5.

3.

Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.

Segarra-Medrano A, Jatem-Escalante E, Quiles-Pérez MT, Salcedo MT, Arbós-Via MA, Ostos H, Valtierra N, Carnicer-Cáceres C, Agraz-Pamplona I.

Nefrologia. 2014 May 21;34(3):353-9. doi: 10.3265/Nefrologia.pre2013.Dec.12291. Epub 2014 Feb 10. English, Spanish.

4.

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ.

N Engl J Med. 2009 Jul 2;361(1):11-21. doi: 10.1056/NEJMoa0810457.

5.

Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.

Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS.

PLoS One. 2013 Apr 26;8(4):e62151. doi: 10.1371/journal.pone.0062151. Print 2013.

6.

PLA2R autoantibodies and recurrent membranous nephropathy after transplantation.

Stahl R, Hoxha E, Fechner K.

N Engl J Med. 2010 Jul 29;363(5):496-8. doi: 10.1056/NEJMc1003066. No abstract available.

PMID:
20818871
7.

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF.

J Am Soc Nephrol. 2012 Oct;23(10):1735-43. Epub 2012 Sep 6.

8.

Membranous nephropathy: from models to man.

Beck LH Jr, Salant DJ.

J Clin Invest. 2014 Jun;124(6):2307-14. doi: 10.1172/JCI72270. Epub 2014 Jun 2. Review.

9.

Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy.

Kimura Y, Miura N, Debiec H, Morita H, Yamada H, Banno S, Ronco P, Imai H.

Clin Exp Nephrol. 2017 Feb;21(1):117-126. doi: 10.1007/s10157-016-1235-2. Epub 2016 Feb 1.

10.

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.

Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1286-91. doi: 10.2215/CJN.07210810. Epub 2011 Apr 7.

11.

Membranous nephropathy and malignancy.

Beck LH Jr.

Semin Nephrol. 2010 Nov;30(6):635-44. doi: 10.1016/j.semnephrol.2010.09.011. Review.

PMID:
21146128
12.

Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?

Hofstra JM, Wetzels JF.

Neth J Med. 2012 Apr;70(3):109-13. Review.

13.

Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy.

Quintana LF, Blasco M, Seras M, Pérez NS, López-Hoyos M, Villarroel P, Rodrigo E, Viñas O, Ercilla G, Diekmann F, Gómez-Roman JJ, Fernandez-Fresnedo G, Oppenheimer F, Arias M, Campistol JM.

Transplantation. 2015 Aug;99(8):1709-14. doi: 10.1097/TP.0000000000000630.

PMID:
25675198
14.

Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.

Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, Jeribi A, Thouret MC, Bernard G, Benzaken S, Lambeau G, Esnault VL.

Nephrol Dial Transplant. 2014 Dec;29(12):2334-42. doi: 10.1093/ndt/gfu252. Epub 2014 Jul 25.

PMID:
25063424
15.

PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.

Debiec H, Ronco P.

N Engl J Med. 2011 Feb 17;364(7):689-90. doi: 10.1056/NEJMc1011678. No abstract available.

PMID:
21323563
16.

Pathogenesis of membranous nephropathy: recent advances and future challenges.

Ronco P, Debiec H.

Nat Rev Nephrol. 2012 Feb 28;8(4):203-13. doi: 10.1038/nrneph.2012.35. Review.

PMID:
22371247
17.

Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.

Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA.

Kidney Int. 2012 Oct;82(7):797-804. doi: 10.1038/ki.2012.209. Epub 2012 Jun 6.

18.

Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.

Ronco P, Debiec H.

J Am Soc Nephrol. 2010 Apr;21(4):564-9. doi: 10.1681/ASN.2009121220. Epub 2010 Feb 25.

19.

Recent advances and prognosis in idiopathic membranous nephropathy.

Segal PE, Choi MJ.

Adv Chronic Kidney Dis. 2012 Mar;19(2):114-9. doi: 10.1053/j.ackd.2012.01.007. Review.

PMID:
22449349
20.

Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens.

Medrano AS, Escalante EJ, Cáceres CC, Pamplona IA, Allende MT, Terrades NR, Carmeno NV, Roldán EO, Agudelo KV, Vasquez JJ.

Biomarkers. 2015 Feb;20(1):77-83. doi: 10.3109/1354750X.2014.993708. Epub 2014 Dec 18.

PMID:
25519165

Supplemental Content

Support Center